No Pain More Gain

Description

NPMG Roll On is a topical formulation designed for localized application. The product is presented in a roll-on dosage form, facilitating ease of use and targeted delivery. The formulation is characterized by its specific blend of active and inactive ingredients, which contribute to its intended therapeutic effects. The appearance of NPMG Roll On is consistent with a clear liquid, ensuring optimal visibility during application.

Uses and Indications

This drug is indicated for the relief of local noninflammatory pain. The No Pain More Gain (NPMG) Roll On formulation provides instant pain relief while simultaneously moisturizing the skin. Utilizing an advanced German formula, NPMG begins to take effect upon contact and offers prolonged pain relief for several hours. The product is designed to penetrate deeply and absorb quickly, leaving a fresh and pleasant scent.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to apply a small amount of the product directly onto the affected area, with a maximum frequency of four times per day. Upon application, a hot sensation indicates that the product is beginning to take effect.

In instances where no heat sensation is experienced within six hours of application, it is recommended to increase the amount used for the subsequent application.

This product is contraindicated for use in children under 12 years of age.

Contraindications

There are no specific contraindications listed for this product. However, it is advised to discontinue use and consult a healthcare professional if any of the following occur: worsening of the condition, skin irritation, or if symptoms persist for more than 7 days or resolve and then recur within a few days.

Warnings and Precautions

For external use only. It is imperative to avoid contact with the eyes and mucous membranes to prevent irritation or injury. The product should not be applied to irritated skin, as this may exacerbate the condition. Additionally, the treated area must not be wrapped, bandaged, or subjected to heat from a heating pad, as these actions can lead to increased absorption and potential adverse effects. The product is contraindicated for use on open wounds or broken skin.

Patients should be advised to discontinue use and contact their healthcare provider if any of the following occur: worsening of the condition, development of skin irritation, or if symptoms persist for more than 7 days. If symptoms resolve and then recur within a few days, medical consultation is also recommended. Regular monitoring of the skin condition is advised to ensure safety and efficacy during treatment.

Side Effects

Patients should be aware that the product is for external use only and must avoid contact with the eyes and mucous membranes. It is contraindicated for use on irritated skin, open wounds, or broken skin. Additionally, patients should not wrap, bandage, or apply a heating pad to the treated area.

In clinical practice, patients are advised to discontinue use and consult a healthcare professional if any of the following occur: worsening of the condition, development of skin irritation, or if symptoms persist for more than 7 days or resolve only to recur within a few days. These precautions are essential to ensure the safe and effective use of the product.

Drug Interactions

No specific drug interactions have been identified in the available data. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of No Pain More Gain (menthol). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not be administered this medication. Safety and efficacy have not been established in this population, and use in younger children is contraindicated.

Geriatric Use

Elderly patients may require careful consideration when prescribing this medication. It is important to note that the use of this medication is contraindicated in children under 12 years of age.

Healthcare providers should exercise caution when administering this medication to geriatric patients, as age-related physiological changes may affect drug metabolism and response. Monitoring for efficacy and adverse effects is recommended, particularly in this population.

Dosage adjustments may be necessary based on individual patient factors, including renal and hepatic function, which can be more variable in elderly patients. Regular assessment and close monitoring are advised to ensure optimal therapeutic outcomes while minimizing potential risks.

Pregnancy

There is no specific information available regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions that should be taken. Healthcare professionals are advised to consider the lack of data when prescribing this medication to pregnant patients. The potential risks and benefits should be carefully evaluated, and alternative treatments may be considered in consultation with the patient. Women of childbearing potential should be informed of the absence of established safety data during pregnancy.

Lactation

There are no specific warnings or recommendations regarding the use of this product in lactating mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the context of overdosage, there is currently no specific information available regarding the effects or management of an overdose for this medication. Healthcare professionals are advised to monitor patients closely for any unusual symptoms or adverse reactions that may arise.

In the absence of detailed overdosage data, it is recommended that standard supportive care measures be implemented. This may include symptomatic treatment and monitoring of vital signs. If an overdose is suspected, healthcare providers should consider contacting a poison control center or seeking guidance from a medical toxicologist for further management recommendations.

As always, maintaining a thorough understanding of the medication's pharmacological profile and potential interactions is essential in the event of an overdose scenario.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion.

Patients should be instructed to stop using the product and consult a doctor if any of the following occur: the condition worsens, skin irritation develops, or if symptoms persist for more than 7 days. Additionally, patients should be informed to seek medical advice if symptoms clear up and then recur within a few days. This guidance is essential to ensure patient safety and effective management of their condition.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light exposure to protect its quality. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

Patients should apply a small amount of the medication directly onto the affected area up to four times a day. Clinicians should advise that this medication is not recommended for use in children under 12 years of age. No further information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for No Pain More Gain, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)